Targeting of Radionuclides and Drugs for the Diagnosis and Treatment of Cancer

  • T. Ghose
  • H. Blair
  • P. Kulkarni
  • K. Vaughan
  • S. Norvell
  • P. Belitsky
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 47)


The application of antibody-linked agents in the diagnosis and treatment of cancer is based on two findings. First, a variety of membrane-bound tumor-associated antigens (TAA) has been serologically defined for both animal and human tumors1,2. Antibodies against many of thse antigens selectively localise in the target tumor in vivo 1,3,4,5. Second, methods are available for linking agents to immunoglubulin molecules with retention of agent and antibody activities1,3.


Diphtheria Toxin Antibody Activity Human Renal Cell Carcinoma Water Soluble Carbodiimide Antitumor Antibody 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    T. Ghose and A.H. Blair, Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects, JNCI 61: 657 (1978).PubMedGoogle Scholar
  2. 2.
    K.R. McIntire, Tumor markers for radioimmunodetection of cancer, Cancer Res. 40: 3083 (1980).PubMedGoogle Scholar
  3. 3.
    T. Ghose, A.H. Blair, K. Vaughan, and P. Kulkarni, Antibody-directed drug targeting in cancer, in: “Targeted Drugs Polymers in Biology and Medicin,” Vol. 2, E. Goldberg, L. Donaruma and O. Vogl, eds., John Wiley and Sons, Inc., New York (in press).Google Scholar
  4. 4.
    T. Ghose, A.H. Blair, R.H. Martin, S.T. Norvell, S. Ramakrish- nan, and P. Belitsky, Tumor imaging by antitumor antibody-linked radionuclides, in: “Tumor Imaging: the Radiochemical Detection of Cancer,” S. Burchiel and B.A. Rhodes, eds., Masson Publishing U.S.A., Inc., New York (in press).Google Scholar
  5. 5.
    T. Ghose, S.T. Norvell, J. Aquino, P. Belitsky, J. Tai, A. Guclu, and A.H. Blair, Localization of 131I-labeled antibodies in human renal cell carcinomas and a mouse hepatoma and correlation with tumor detection by photoscanning, Cancer Res. 40: 3018 (1980).PubMedGoogle Scholar
  6. 6.
    T. Ghose and S.P. Nigam, Antibody as carrier of chlorambucil, Cancer 29: 1398 (1972).PubMedCrossRefGoogle Scholar
  7. 7.
    T. Ghose, S.T. Norvell, A. Guclu, D. Cameron, A. Bodurtha, and A.S. MacDonald, Immunochemotherapy of cancer with chlorambucil-carrying antibody, Brit. Med. J., 3: 495 (1972).PubMedCrossRefGoogle Scholar
  8. 8.
    T. Ghose, A. Guclu, and J. Tai, Suppression of an AKR lymphoma by antibody and chlorambucil, JNCI 55: 1353 (1975).PubMedGoogle Scholar
  9. 9.
    J. Tai, A.H. Blair, and T. Ghose, Tumor inhibition by chlorambucil covalently linked to antitumor globulin, Eur. J. Cancer, 15: 1357 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    D.A.L. Davies and G.J. O’Neill, In-vivo and in-vitro effects of tumor specific antibodies with chlorambucil, Brit. J. Cancer 1: 285 (1973).Google Scholar
  11. 11.
    R.D. Rubens and R. Dulbecco, Augmentation of cytotoxic drug action by antibodies directed at cell surface, Nature, 248: 81 (1974).PubMedCrossRefGoogle Scholar
  12. 12.
    H.F. Dullens, R.A. DeWeger, C. Vennegoor, and W. DenOtter, Antitumor effect of chlorambucil-antibody complexes in a murine melanoma system, Eur. J. Cancer, 15: 69 (1979).PubMedCrossRefGoogle Scholar
  13. 13.
    F.L. Moolten, S.R. Cooperband, Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells, Science, 169: 68 (1970).PubMedCrossRefGoogle Scholar
  14. 14.
    P.N. Kulkarni, A.H. Blair, and T. Ghose, Covalent binding of methotrexate to immunoglobulins and its effect on drug and antibody activities, Federation Proc. 40: 642 (1981).Google Scholar
  15. 15.
    P.N. Kulkarni, A.H. Blair, and T. Ghose, Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo, Cancer Res, (in press).Google Scholar
  16. 16.
    S. Burstein and R. Knapp, Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates, J. Med. Chem. 20: 950 (1977).PubMedCrossRefGoogle Scholar
  17. 17.
    Z.A. Latif, B.B. Lozzio, C.J. Wust, S. Krauss, M.C. Aggio, and C.B. Lozzio, Evaluation of drug-antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice, Cancer, 45: 1326 (1980).PubMedCrossRefGoogle Scholar
  18. 18.
    T. Ghose, J. Tai, A. Guclu, S.T. Norvell, A.H. Blair and J. Aquino, Use of cell surface localizing antihepatoma antibody for tumor imaging and therapy with drug-linked antibody, Transplant. Proc., 12: 192 (1980).PubMedGoogle Scholar
  19. 19.
    I. Kimura, T. Ohnoshi, T. Tsubota, Y. Sato, T. Kobayashi and S. Abe, Production of tumor antibody-neocarzinostatin (NCS) conjugate and its biological activites, Cancer Immunol. Immunother. 7: 235 (1980).CrossRefGoogle Scholar
  20. 20.
    M. Belles-Isles and M. Page, In-vitro activity of daunomycinanti-alphafoetoprotein conjugate on mouse hepatoma cells, Brit. J. Cancer, 41: 841 (1980).PubMedCrossRefGoogle Scholar
  21. 21.
    F.H. Lee, I. Berczi, S. Fujimoto and A.H. Sehon, The use of anti-fibrin antibodies for the destruction of tumor cells III Complete regression of MC-D sarcoma in guinea pigs by conjugates of daunomycin with antifibrin antibodies, Cancer Immunol. Immunother., 5: 201 (1978).CrossRefGoogle Scholar
  22. 22.
    D.G. Gilliland, Z. Steplewski, R. Collier, K.F. Mitchell, T.H. Chang and H. Koprowski, Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells, Proc. Natl. Acad. Sci. USA, 77: 4539 (1980).PubMedCrossRefGoogle Scholar
  23. 23.
    Y. Masuho, T. Hara, and T. Noguchi, Preparation of a hybrid of fragment Fab’ of antibody and fragment A of diphtheria and its cytotoxicity. Biochem. Biophys. Res. Commun. 90: 320 (1979).PubMedCrossRefGoogle Scholar
  24. 24.
    P.E. Thorpe, W.C.J. Ross, A.J. Cumber, C.A. Hinson, D.C. Edwards, and A.J.S. Davies, Toxicity of diphtheria toxin for lymphoblastoid cells is increased by conjugation to antilymphocytic globulin, Nature, 271: 752 (1978).PubMedCrossRefGoogle Scholar
  25. 25.
    W.C.J. Ross, P.E. Thorpe, A.J. Cumber, D.C. Edwards, C.A. Hinson, and A.J.S. Davies, Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte) globulin or its F(abl)2 fragment. Eur. J. Biochem. 104: 381 (1980).PubMedCrossRefGoogle Scholar
  26. 26.
    K.A. Krolick, C. Villemez, P. Isakson, J.W. Uhr, and E.S. Vitetta, Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin, Proc. Natl. Acad. Sci. USA, 77: 5419 (1980).PubMedCrossRefGoogle Scholar
  27. 27.
    H.E. Blythman, P. Casellas, 0. Gros, P. Gros, F.K. Jansen, F. Paolucci, B. Pau, and H. Vidal, Immunotoxins:hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells, Nature 290: 145 (1981).PubMedCrossRefGoogle Scholar
  28. 28.
    F.K. Jansen, H.E. Blythman, D. Carriere, P. Casellas, J. Diaz, P. Gros, J.R. Hennequin, F. Apolucci, B. Pau, H. Poncelet, G. Richer, S.L. Salhi, H. Vidal, and G.A. Voisin, High specific cytotoxicity of antibody-toxin hybrid molecules (immunotoxins) for target cells. Immunol. Lett. 2: 97 (1980).CrossRefGoogle Scholar
  29. 29.
    R.J. Youle, and D.M. Neville, Jr., Anti-thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific Toxin, Proc. Natl. Acad. Sci. USA, 77: 5483 (1980).PubMedCrossRefGoogle Scholar
  30. 30.
    V. Raso, and T. Griffin, Specific cytotoxicity of a human immunoglobulin-directed Fabl-ricin A chain conjugate, J. Immunol. 125: 2610 (1980).PubMedGoogle Scholar
  31. 31.
    E. Hurwitz, R. Maron, A. Bernstein, M. Wilchek, M. Sela, and R. Arnon, The effect in vivo of chemotherapeutic drug-antibody conjugates in two murine experimental tumor systems, Int. J. Cancer, 21: 747 (1978).PubMedCrossRefGoogle Scholar
  32. 32.
    T. Ghose, S. Ramakrishnan, P. Kulkarni, A.H. Blair, K. Vaughan, H. Nolido, S.T. Norvell and P. Belitsky, Use of antibodies against tumor-associated antigens for cancer diagnosis and treatment, Transplant. Proc., in press.Google Scholar
  33. 33.
    A. Guclu, T. Ghose, J. Tai and M. Mammen, Binding of chlorambucil with antitumor globulins and its effect on drug and antibody activities, Eur. J. Cancer, 12: 95 (1976).PubMedCrossRefGoogle Scholar
  34. 34.
    T. Ghose, S.T. Norvell, A. Guclu, A. Bodurtha, J. Tai, and A.S. MacDonald, Immunochemotherapy of malignant melanoma with chlorambucil-bound antimelanoma globulins: preliminary results in patients with disseminated disease, JNCI, 58: 845 (1977).PubMedGoogle Scholar
  35. 35.
    T. Chose, S.T. Norvell, A. Guclu and A.S. MacDonald, Immunochemotherapy of human malignant melanoma with chlorambucilcarrying antibody, Eur. J. Cancer, 11: 321 (1975).CrossRefGoogle Scholar
  36. 36.
    A. Guclu, J. Tai, and T. Ghose, Endocytosis of chlorambucil-bound antitumor globulin following “capping”in EL4 lymphoma cells, Immunol. Commun. 4: 229 (1975).PubMedGoogle Scholar
  37. 37.
    T. Chose, J. Tai, A. Guclu, S.T. Norvell, A. Bodurtha, J. Aquino and A.S. MacDonald, Antibodies as carriers of radionuclides and cytotoxic drugs in the treatment and diagnosis of cancer, Ann. NY Acad. Sci., 277: 671 (1976).CrossRefGoogle Scholar
  38. 38.
    D.G. Johns and J.R. Bertino, Folate antagonists, in: “Cancer Medicine,” J.F. Holland and E. Frei, eds., Lea & Febiger, Philadelphia (1973).Google Scholar
  39. 39.
    E. Hurwitz, R. Levy, R. Maron, M. Wilcheck, R. Arnon and M. Sela, The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities, Cancer Res, 35: 1175 (1975).PubMedGoogle Scholar
  40. 40.
    W.C. Shen and H.J.P. Ryser, Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins, Proc. Natl. Acad. Sci. USA, 75: 1872 (1978).PubMedCrossRefGoogle Scholar
  41. 41.
    D. Pressman, and G. Keighley, The zone of activity of antibodies as determined by the use of radioactive tracer; the zone of activity of nephrotoxic antikidney serum, J. Immunol., 59: 141 (1948).PubMedGoogle Scholar
  42. 42.
    T. Ghose, A. Guclu, J. Tai, A.S. MacDonald, S.T. Norvell and J. Aquino, Antibody as carrier of 1311 in cancer diagnosis and treatment, Cancer, 36: 1646 (1975).PubMedCrossRefGoogle Scholar
  43. 43.
    D. Pressman, The development and use of radiolabeled antitumor antibodies, Cancer Res, 40: 2960 (1980).PubMedGoogle Scholar
  44. 44.
    T. Chose, M. Cerini, M. Carter and R.C. Nairn, Immunoradioactive agent against cancer, Brit. Med. J., 1: 90 (1967).CrossRefGoogle Scholar
  45. 45.
    T. Chose, J. Tai, J. Aquino, A. Guclu, S. Norvell and A.S. MacDonald, Tumor localization of 131I-labeled antibodies by radionuclide imaging, Radiol., 116: 445 (1975).Google Scholar
  46. 46.
    R.C. Nairn, J. Philip, T. Chose, I.B. Porteous, and J.E. Fothergill, Production of a precipitin against renal cancer, Brit. Med. J., 1: 1702 (1963).PubMedCrossRefGoogle Scholar
  47. 47.
    T. Chose, P. Belitsky, J. Tai, and D.T. Janigan, Production and characterization of xenogeneic antisera to a human renal cell carcinoma associated antigen, JNCI, 63: 301 (1979).Google Scholar
  48. 48.
    P. Belitsky, T. Chose, J. Aquino, S.T. Norvell and A.H. Blair, Radionuclide imaging of primary renal-cell carcinoma by labeled antitumor antibody, J. Nucl. Med., 19: 427 (1978).PubMedGoogle Scholar
  49. 49.
    P. Belitzky, T. Chose, J. Aquino, J. Tai, and A.S. MacDonald, Radionuclide imaging of metastases from renal-cell carcinoma patients by 1311-labeled antitumor antibody, Radiol., 126: 515 (1978).Google Scholar
  50. 50.
    F.J. Primus, R. MacDonald, D.M. Goldenberg, H.J. Hansen, Localization of GW-39 human tumors in hamsters by affinity-purified antibody to carcinoembryonic antigen, Cancer Res., 37: 1544 (1977).PubMedGoogle Scholar
  51. 51.
    K. Imai, A.K. Ng, and S. Ferrone, Characterization of monoclonal antibodies to human melanoma-associated antigens, JNCI, 66: 489 (1981).PubMedGoogle Scholar
  52. 52.
    S. Nord, and I.L. Weissman, Radiolabeled antitumor antibodies. II. Quantitative analysis of Moloney tumor antigens on Moloney lymphoma cells (LSTRA), JNCI, 53: 125 (1974).PubMedGoogle Scholar
  53. 53.
    S. Olsnes, Directing toxins to cancer cells, Nature, 290: 84 (1981).PubMedCrossRefGoogle Scholar
  54. 54.
    C. McGaughey, Feasibility of tumor immunoradiotherapy using radio-iodinated antibodies to tumor-specific cell membrane antigens with emphasis on leukemias and early metastases, Oncology, 29: 302 (1974).PubMedCrossRefGoogle Scholar
  55. 55.
    W.F. Bale, M.A. Contreras, and E.P. Grady, Factors influencing localization of labeled antibodies in tumors, Cancer Res., 40: 2965 (1980).PubMedGoogle Scholar
  56. 56.
    M.J. Izzo, D.J. Buchsbaum and W.F. Bale, Localization of an 125I-labeled rat transplantation antibody in tumors carrying the corresponding antigen, Proc. Soc. Exp. Biol. Med., 139: 1185 (1972).PubMedGoogle Scholar
  57. 57.
    D.M. Goldenberg, F. Deland, E. Kim, S. Bennett, F.J. Primus, J.R. Van Nagel, Jr., N. Estes, P. Desimone and P. Rayburn, Use of radiolabeled antibodies of carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning, New Engl. J. Med., 298: 1384 (1978).PubMedCrossRefGoogle Scholar
  58. 58.
    J.P. Mach, S. Carrel, M. Forni, J. Ritschard, A. Donath and P. Alberto, Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma, New Engl. J. Med., 303: 5 (1980).PubMedCrossRefGoogle Scholar
  59. 59.
    B. Ballou, G. Levine, T.R. Hakala and D. Solter, Tumor location detected with radioactively labeled monoclonal antibody and external scintigraphy, Science, 206: 844 (1979).PubMedCrossRefGoogle Scholar
  60. 60.
    L.L. Houston, R.C. Nowinski and I.D. Bernstein, Specific in vivo localization of monoclonal antibodies directed against the Thy 1.1 antigen, J. Immunol., 125: 837 (1980).PubMedGoogle Scholar
  61. 61.
    G. Subramanian, B.A. Rhodes, J.F. Cooper, V.J. Sodd, eds., “Radiopharmaceuticals”, Society of Nuclear Medicine, New York (1975).Google Scholar
  62. 62.
    B.A. Khau, J.T. Fallon, H.W. Strauss and E. Haber, Myocardial infarct imaging of antibodies to canine cardiac myosin with Indium-111-diethylenetriamine, Science, 209: 295 (1980).CrossRefGoogle Scholar
  63. 63.
    T. Ghose, and A. Guclu, Cure of a mouse lymphoma with radio-iodinated antibody, Eur. J. Cancer, 10: 787 (1974).PubMedCrossRefGoogle Scholar
  64. 64.
    K.G. Hofer, G. Keough and J.M. Smith, Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation, Cur. Topics Radiation Res. Quarterly, 12: 335 (1977).Google Scholar
  65. 65.
    M.F. Hawthorne and R.J. Wiersema, Preparation of tumor specific boron compounds. 1. In-vitro studies using boron-labeled antibodies and elemental boron as neutron targets, J. Med. Chem. 15: 449 (1972).PubMedCrossRefGoogle Scholar
  66. 66.
    A.G. Mallinger, E.L. Jozwiak, Jr., and J.C. Carter, Preparation of boron-containing bovine Y -globulin as a model compound for a new approach to slow neutron therapy of tumors, Cancer Res., 32: 1947 (1972).PubMedGoogle Scholar
  67. 67.
    L.E. Farr and T. Koniwowski, Long range effects of neutron capture therapy of cancer in mice, Int. J. Nucl. Med. Biol., 3: 1 (1976).PubMedCrossRefGoogle Scholar
  68. 68.
    T. Saigusa and Y. Veno, Calculated responses to a thermal neutron beam for hamster and HeLa cells containing Boron-10 at different concentrations, Phys. Med. Biol., 23: 748 (1978).CrossRefGoogle Scholar
  69. 69.
    T. Ghose and M. Cerini, Radiosensitization of Ehrlich ascites tumour cells by a specific antibody, Nature, 222: 993 (1969).PubMedCrossRefGoogle Scholar
  70. 70.
    S.E. Order, J.L. Klein, D. Ettinger, P. Alderson, S. Siegelman, and P. Leichner, Use of isotopic immunoglobulin in therapy, Cancer Res., 40: 3001 (1980).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • T. Ghose
    • 1
  • H. Blair
    • 2
  • P. Kulkarni
    • 1
  • K. Vaughan
    • 3
  • S. Norvell
    • 4
  • P. Belitsky
    • 5
  1. 1.Departments of PathologyDalhousie UniversityCanada
  2. 2.Departments of BiochemistryDalhousie UniversityCanada
  3. 3.Department of ChemistrySaint Mary’s UniversityHalifaxCanada
  4. 4.Departments of SurgeryDalhousie UniversityHalifaxCanada
  5. 5.Departments of UrologyDalhousie UniversityHalifaxCanada

Personalised recommendations